Immunome (IMNM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Voting matters and shareholder proposals
Election of three Class III directors to serve until the 2029 Annual Meeting or until successors are qualified.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory approval of named executive officer compensation (say-on-pay).
Advisory vote on the preferred frequency of future say-on-pay votes, with 'Year' as the recommended frequency.
Board recommends voting 'For' all proposals and nominees.
Board of directors and corporate governance
Three nominees for Class III director positions: James Boylan, Sandra M. Swain, M.D., and Philip Wagenheim.
Directors to serve until 2029 or until successors are elected and qualified.
Executive compensation and say-on-pay
Advisory vote to approve compensation of named executive officers.
Advisory vote to determine frequency of future say-on-pay votes, with annual voting recommended.
Latest events from Immunome
- All proposals passed, including annual executive compensation votes; no questions submitted.IMNM
AGM 202610 Jun 2026 - Varegacestat shows strong efficacy as launch nears; ADC pipeline and cash runway support growth.IMNM
Goldman Sachs 47th Annual Global Healthcare Conference 20269 Jun 2026 - Varegacestat met all Phase 3 endpoints in desmoid tumors, with NDA filed and strong pipeline progress.IMNM
Investor presentation31 May 2026 - NDA filed for varegacestat after strong Phase 3; Q1 net loss $53.8M, cash $582.7M.IMNM
Q1 202612 May 2026 - 2025 achievements drove pipeline and share growth; Board recommends all proposals at 2026 meeting.IMNM
Proxy filing24 Apr 2026 - Lead asset Varegacestat nears FDA submission after strong phase III data; ADC pipeline advances.IMNM
Leerink Global Healthcare Conference 202610 Mar 2026 - Positive Phase 3 results and strong financing position support multiple 2026 milestones.IMNM
Q4 20253 Mar 2026 - Varegacestat advances toward NDA as a robust ADC pipeline and radiotherapy program gain momentum.IMNM
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Positive Phase 3 data for varegacestat and a deep ADC pipeline drive oncology innovation.IMNM
Corporate presentation3 Mar 2026